MORRIS PLAINS, N.J., Feb. 25 /PRNewswire-FirstCall/ -- Immunomedics, Inc.
(Nasdaq: IMMU) today announced that Cynthia L. Sullivan, President and Chief
Executive Officer, is scheduled to present at the Lehman Brothers 7th Annual
Global Healthcare Conference in Miami, Florida at 3:45 p.m. on Wednesday,
March 3, 2004. Ms. Sullivan will provide a corporate overview, including
comments on the Company's product portfolio.
The presentation will be webcast live and may be accessed by visiting the
Company's website at http://www.immunomedics.com. Investors can access the webcast
under the "Company Presentation" section our website.
Immunomedics is a biopharmaceutical company focused on the development,
manufacture and commercialization of diagnostic imaging and therapeutic
products for the detection and treatment of cancer and other serious diseases.
Integral to these products are highly specific monoclonal antibodies and
antibody fragments designed to deliver radioisotopes and chemotherapeutic
agents to tumors and other sites of disease. Immunomedics has nine
therapeutic product candidates in clinical or near clinical development and
has two marketed diagnostic imaging products. The most advanced therapeutic
product candidates are LymphoCide(R) (epratuzumab), for which certain Phase II
clinical trials for the treatment of non-Hodgkin's lymphoma have already been
completed, and CEA-Cide(R) (labetuzumab), which is in Phase I/II clinical
trials for the treatment of certain solid tumors.
This release, in addition to historical information, contains forward-
looking statements made pursuant to the Private Securities Litigation Reform
Act of 1995. Such statements, including statements regarding clinical trials,
involve significant risks and uncertainties and actual results could differ
materially from those expressed or implied herein. Factors that could cause
such differences include, but are not limited to, risks associated with new
product development (including clinical trials outcome and regulatory
requirements/actions), competitive risks to marketed products and availability
of financing and other sources of capital, as well as the risks discussed in
the Company's Annual Report on Form 10-K for the year June 30, 2003.
Company Contact: Trish Merwin, Investor Relations, (973) 605-8200. Visit
the Company's web site at http://www.immunomedics.com.
SOURCE Immunomedics, Inc.
 back to top
Related links:
http://www.Immunomedics.com
Company News On-Call:
http://www.prnewswire.com/comp/113121.html
CONTACT:
Trish Merwin, Investor Relations of
Immunomedics, Inc., +1-973-605-8200
|
